TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11491177

Group type: EXPERIMENTAL
Intervention: Influenza vaccines (split product and surface antigen vaccines)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral drugs (amantadine and rimantadine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New antiviral agents targeting influenza neuraminidase
Number of subjects: 0
Study: 9396433

Group type: EXPERIMENTAL
Intervention: Nadroparin (0.6 mL of 10,250 anti-Xa IU/mL)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 354
Study: 7970790

Group type: EXPERIMENTAL
Intervention: Skin end‐point titration based immunotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prick testing based immunotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scratch testing based immunotherapy
Number of subjects: 30
Study: 3581636

Group type: EXPERIMENTAL
Intervention: Slo‐bid Gyrocaps
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Theo‐dur Sprinkle
Number of subjects: 15
Study: 29661642

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 688

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 688
Study: 27149496

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFT) during the temporary stoma period
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no BFT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFT)
Number of subjects: 56
Study: 24275838

Group type: EXPERIMENTAL
Intervention: Valsartan-amlodipine (80/5 mg, then 160/10 mg)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Atenolol-amlodipine (50/5 mg, then 100/10 mg)
Number of subjects: 373
Study: 22554695

Group type: EXPERIMENTAL
Intervention: Extended nasolabial flap
Number of subjects: 20

Group type: COMPARATOR
Intervention: Platysma myocutaneous muscle flap
Number of subjects: 20
Study: 20715088

Group type: EXPERIMENTAL
Intervention: Endoscopic ethmoidectomy, middle meatus antrostomy, and excision of the cysts (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ethmoidectomy and antrostomy without cyst detachment (group B)
Number of subjects: 80
Study: 18280619

Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed formula (EHF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Partially hydrolysed formula (PHF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intact protein formula (IPF)
Number of subjects: 20
Study: 15902987

Group type: EXPERIMENTAL
Intervention: Interval cycling exercise (INT) consisting of seven 2 min work intervals at 90% VO2max, followed by 3 min of relief at 30% VO2max.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous cycling exercise (CON) consisting of 30 to 32 min at 65% VO2max.
Number of subjects: 12
Study: 12133124

Group type: EXPERIMENTAL
Intervention: Gradual benzodiazepine taper combined with cognitive-behavioural therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard withdrawal treatment
Number of subjects: 76
Study: 10224354

Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25 (humanized monoclonal antibody against IgE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25
Number of subjects: 0
Study: 7776406

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1691367

Group type: EXPERIMENTAL
Intervention: 20 mg felodipine extended-release (ER) tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 523172

Group type: EXPERIMENTAL
Intervention: 1.0 mg FK (synthetic enkephalin analogue) intramuscularly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 mg FK intramuscularly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25 mg FK intramuscularly
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg betazole (placebo)
Number of subjects: 0
Study: 30869570

Group type: EXPERIMENTAL
Intervention: Deferred consent enrollment
Number of subjects: 56
Study: 27794193

Group type: EXPERIMENTAL
Intervention: Water sweetened with saccharin (5 mg/kg body weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Water sweetened with saccharin
Number of subjects: 40
Study: 25455437

Group type: EXPERIMENTAL
Intervention: Arm crank ergometry (ACE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cycle ergometry (CE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Treadmill walking (TM)
Number of subjects: 9
Study: 23636153

Group type: EXPERIMENTAL
Intervention: SCT-based education intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study: 22143220

Group type: EXPERIMENTAL
Intervention: HPV vaccination education
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 125
Study: 19186901

Group type: EXPERIMENTAL
Intervention: Receiving voice (objectively fair procedures)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Voice x Identity Violation interaction
Number of subjects: 385
Study: 17076823

Group type: EXPERIMENTAL
Intervention: 35 mg cortisol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15598481

Group type: EXPERIMENTAL
Intervention: Wood creosote 135 mg (<or=5 doses/d)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Loperamide 4 mg (loading dose) followed by 2 mg (<or=8 mg/d) after each loose stool
Number of subjects: 123
Study: 11386493

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Self-help manual
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fluoxetine and self-help manual
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 10809268

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia with naloxone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Methohexital anesthesia with naloxone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both anesthetics with naloxone
Number of subjects: 25
Study: 8820889

Group type: EXPERIMENTAL
Intervention: Short, intermittent contractions (IC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Long, continuous contractions (CC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study: 1317343

Group type: EXPERIMENTAL
Intervention: 15 mg/kg immune serum globulin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg immune serum globulin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (1 microgram/dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (0.5 micrograms/dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (0.25 micrograms/dose)
Number of subjects: 10
Study: 3934956

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 0
Study: 29465549

Group type: EXPERIMENTAL
Intervention: Metabolic rehabilitation program composed of aerobic and resisted exercises, performed for 12 weeks, in 3 weekly meetings of 60 minutes each.
Number of subjects: 0
Study: 26982602

Group type: EXPERIMENTAL
Intervention: Pregabalin-Duloxetine Combination
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25279525

Group type: EXPERIMENTAL
Intervention: Group 3 (Class II subdivision)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group 2 (Class II)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group 1 (Class I)
Number of subjects: 90
Study: 22865033

Group type: EXPERIMENTAL
Intervention: Normal saline alternating with 5% dextrose at rate of 175 ml/h
Number of subjects: 250

Group type: COMPARATOR
Intervention: Normal saline alone
Number of subjects: 250
Study: 20578975

Group type: EXPERIMENTAL
Intervention: Ball emitting broadband sound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-sound group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18051011

Group type: EXPERIMENTAL
Intervention: Incremental technique (four oblique layers) with total-etch adhesive (Single Bond)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flowable composite as liner and bulk technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bulk technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Light cone technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Incremental technique with self-etch adhesive (AdheSE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total-etch adhesive (Single Bond) with incremental technique
Number of subjects: 60
Study: 15632026

Group type: EXPERIMENTAL
Intervention: Duke treadmill score (DTS)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Radionuclide angiography with ejection fraction (RNA-EF)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: SPECT perfusion imaging
Number of subjects: 997
Study: 12184476

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 568

Group type: COMPARATOR
Intervention: Left-handers
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Left-handed males
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 568
Study: 10639704

Group type: EXPERIMENTAL
Intervention: Vaginal delivery (25 women)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vaginal delivery (multiparae)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vaginal delivery (primiparae)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (6 nulliparous women)
Number of subjects: 25
Study: 7846539

Group type: COMPARATOR
Intervention: etoposide/cisplatin (VP)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: etoposide/ifosfamide/cisplatin (VIP)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: daily oral etoposide/ifosfamide/cisplatin
Number of subjects: 171
Study: 2185963

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 65

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pirprofen
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 65

Group type: COMPARATOR
Intervention: Suprofen
Number of subjects: 65
Study: 30580454

Group type: EXPERIMENTAL
Intervention: saxagliptin (5 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study: 29083936

Group type: EXPERIMENTAL
Intervention: Combination therapy (50 mg losartan/12.5 mg HCTZ)
Number of subjects: 201

Group type: COMPARATOR
Intervention: High-dose therapy (100 mg losartan)
Number of subjects: 201
Study: 27538188

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 10154
Study: 24494695

Group type: EXPERIMENTAL
Intervention: Prior mental health specialty treatment
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Quality of life (every one-unit decrease)
Number of subjects: 107
Study: 22115823

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 0.4 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenous morphine 5 mg
Number of subjects: 89
Study: 19562362

Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 18391460

Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) and iron for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Iron only for 8 weeks (Control)
Number of subjects: 16
Study: 16317534

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/daily) for a maximum of 2 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard therapy (diclofenac 100 mg/daily plus aescin 80 mg/daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 12883407

Group type: EXPERIMENTAL
Intervention: Propofol (target-controlled infusion at concentrations of 2, 4, or 6 microg/ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Remifentanil (increasing concentrations from 0 to 7 ng/ml)
Number of subjects: 30
Study: 10546920

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 18
Study: 8914115

Group type: EXPERIMENTAL
Intervention: Nicotine skin patches (placebo, low 7 mg/day, medium 14 mg/day, high 21 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo nicotine patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine skin patches (all doses)
Number of subjects: 0
Study: 1711261

Group type: EXPERIMENTAL
Intervention: 3 X 500 ml hydroxyethylstarch 6% 0.62
Number of subjects: 207

Group type: COMPARATOR
Intervention: 3 X 5000 IE unfractionated heparin
Number of subjects: 207
Study: 6406947

Group type: EXPERIMENTAL
Intervention: Flutonidin (F) 2 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clonidine (C) 0.3 mg/day
Number of subjects: 30
Study: 30629889

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metformin (completers)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo + non-completers
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insulin resistance group
Number of subjects: 15
Study: 29191561

Group type: EXPERIMENTAL
Intervention: Nexvax2 starting dose of 3μg in cohort 1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nexvax2 starting dose of 30μg in cohort 1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nexvax2 starting dose of 3μg in cohort 2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nexvax2 starting dose of 3μg in cohort 3
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nexvax2 treatment at dose levels from 150μg to 900μg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nexvax2 treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 26577402

Group type: EXPERIMENTAL
Intervention: Eban HIV risk‐reduction intervention
Number of subjects: 535

Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 535
Study: 25126888

Group type: EXPERIMENTAL
Intervention: Media literacy program Vernetzte www.Welten
Number of subjects: 2303

Group type: COMPARATOR
Intervention: Control group (regular class)
Number of subjects: 2303
Study: 21903027

Group type: EXPERIMENTAL
Intervention: Sertraline plus omega-3
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 105
Study: 18670195

Group type: EXPERIMENTAL
Intervention: Formulation 13
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Formulation 14
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Formulation 17
Number of subjects: 71
Study: 17451570

Group type: EXPERIMENTAL
Intervention: Strict gluten-free diet with good clinical response
Number of subjects: 31
Study: 15154363

Group type: EXPERIMENTAL
Intervention: Amino acid addition with standard therapy
Number of subjects: 0
Study: 12235596

Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dynamic resistance training
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 9678528

Group type: EXPERIMENTAL
Intervention: Serum free IGF-I
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Total serum IGF-I
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Free and total IGF-I
Number of subjects: 218
Study: 7516019

Group type: COMPARATOR
Intervention: Bisoprolol (5 mg i.v. infusion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg oral daily for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2683568

Group type: EXPERIMENTAL
Intervention: Ginger root (Zingiber officinale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29554385

Group type: EXPERIMENTAL
Intervention: Intravitreous aflibercept injection (IAI) with a fixed bimonthly regimen for the first 2 years, followed by routine clinical practice regimen in the third year.
Number of subjects: 18
Study: 27402004

Group type: EXPERIMENTAL
Intervention: CFE + CA
Number of subjects: 155

Group type: COMPARATOR
Intervention: CFE
Number of subjects: 155
Study: 26083958

Group type: EXPERIMENTAL
Intervention: Varenicline (Chantix)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22999261

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg twice daily; PO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metformin (750 mg twice daily; PO)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 21371770

Group type: EXPERIMENTAL
Intervention: 600 mg lipoic acid (LA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 800 mg α-tocopherol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 800 mg α-tocopherol + 600 mg lipoic acid (LA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18315636

Group type: EXPERIMENTAL
Intervention: Rotational technique with cuff partially inflated
Number of subjects: 168

Group type: COMPARATOR
Intervention: Lateral technique with cuff partially inflated
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard Brain technique
Number of subjects: 168
Study: 16223655

Group type: EXPERIMENTAL
Intervention: Structural equation modeling (SEM) technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Then test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized approach
Number of subjects: 0
Study: 12057717

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) at a dose of 1.8 g/day orally for 5-6 weeks; 3 g/day for massively obese subjects
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10079438

Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with nonperforating deep sclerectomy (P-DS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phacoemulsification combined with trabeculectomy (P-T)
Number of subjects: 60
Study: 7673531

Group type: EXPERIMENTAL
Intervention: Parent focus intervention
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Teen focus intervention
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Parent and teen focus intervention
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Self-directed change (materials only)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (quasi-experimental)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Parent focus condition
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Aggregated high-risk youths intervention
Number of subjects: 158
Study: 2282293

Group type: EXPERIMENTAL
Intervention: Low osmolar contrast media
Number of subjects: 0

Group type: COMPARATOR
Intervention: High osmolar contrast media
Number of subjects: 0
Study: 7175716

Group type: EXPERIMENTAL
Intervention: 0.5 g probenecid
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1.0 g probenecid
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 2.0 g probenecid
Number of subjects: 3
Study: 30102620

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking at the mother's breast (3 times a day for 5 minutes until nutritive breastfeeding started)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard care (nonnutritive sucking on a finger during gavage feeds)
Number of subjects: 9
Study: 29449764

Group type: EXPERIMENTAL
Intervention: Neuroplasticity explanation with manual therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mechanical explanation with manual therapy
Number of subjects: 62
Study: 26374743

Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC) 3 g/day (1.5 g twice daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 24274912

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Colistin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (spontaneous eradication)
Number of subjects: 152
Study: 21337259

Group type: EXPERIMENTAL
Intervention: Targeted mental imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goal intention mental imagery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active rehearsal (Control)
Number of subjects: 0
Study: 19608151

Group type: EXPERIMENTAL
Intervention: Light-intensity resistance exercise training (n=80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (n=80)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Light-intensity resistance exercise training
Number of subjects: 160
Study: 17631083

Group type: EXPERIMENTAL
Intervention: Continuation of digoxin therapy
Number of subjects: 7788
Study: 14716705

Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg b.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg per day for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study: 12803656

Group type: EXPERIMENTAL
Intervention: Current treatments for MG
Number of subjects: 0
Study: 9845709

Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard triple-drug immunosuppressive therapy (cyclosporine, azathioprine, and prednisone)
Number of subjects: 60
Study: 7852209

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogenic blood transfusion
Number of subjects: 0
Study: 3188866

Group type: EXPERIMENTAL
Intervention: Active physical therapy combined with 2 hours of passive knee motion twice daily from 2-12 days after total knee arthroplasty
Number of subjects: 54

Group type: COMPARATOR
Intervention: Active physical therapy only
Number of subjects: 54